[Therapeutics future of liposomes (author's transl)].
The possibility to use the liposomes as drug vehicles has been largely investigated in recent years. Most of the studies have been carried out in animals and are related to disease involving predominantly the reticulohistiocytic system. Attempts to use these liposomes orally (induced diabetes) or locally (induced arthritis) are also reported. Further trials are required to get a better knowledge of the mechanisms involved in the exchanges between the cell membrane and the liposome the latter being variable as regards its composition, size and permeability according to the various investigators; the adjustment to the liposome of a complex capable to electively direct it towards the target organ is studied.
D000284:Administration, Oral; D000328:Adult; D000818:Animals; D001168:Arthritis / Q000188:drug therapy; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D005260:Female; D005776:Gaucher Disease / Q000188:drug therapy; D006009:Glycogen Storage Disease Type II / Q000188:drug therapy; D006801:Humans; D006819:Hyaline Membrane Disease / Q000188:drug therapy; D007223:Infant; D007231:Infant, Newborn; D007275:Injections, Intravenous; D007328:Insulin / Q000008:administration & dosage; D007898:Leishmaniasis, Visceral / Q000188:drug therapy; D007942:Leukemia, Experimental / Q000188:drug therapy; D008081:Liposomes / Q000008:administration & dosage / Q000627:therapeutic use*; D010539:Permeability; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D011817:Rabbits; D051381:Rats
D007328:Insulin; D008081:Liposomes; D004364:Pharmaceutical Preparations
L'avenir thérapeutique des liposomes.